benlysta

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. Benlysta is a medication for people with lupus that can help manage symptoms and prevent flares. Learn how it works, who should take it, how much it costs, and more from the National Resource Center on Lupus. Find out the answers to common questions about Benlysta and its approval, side effects, and clinical trials. BENLYSTA is a monoclonal antibody that inhibits B lymphocyte stimulator (BLyS) and targets underlying disease in lupus and lupus nephritis. Learn how to access BENLYSTA, see its clinical data, safety data, and peer perspectives. Benlysta is a monoclonal antibody that affects the immune system and is used to treat active systemic lupus erythematosus (SLE) and lupus nephritis. It is given as an infusion or subcutaneous injection every 2 to 4 weeks. Learn about warnings, interactions, and FAQs from this web page. Overview. Benlysta is a medicine used as an add-on treatment in patients aged 5 years and older with systemic lupus erythematosus (SLE), a disease in which the immune system (the body’s natural defences) attacks normal cells and tissues, causing inflammation and organ damage. Benlysta is a biologic medication that treats lupus by weakening a specific part of your immune system. It comes in two forms: an injection or a liquid solution. Learn about its side effects, cost, uses, dosage, and how it’s used for lupus. BENLYSTA (belimumab) for injection is a sterile, preservative-free, lyophilized powder for reconstitution and dilution prior to intravenous infusion provided in single‑dose glass vials with a rubber stopper (not made with natural rubber latex) and a flip‑off seal. Each 5‑mL vial contains 120 mg of belimumab. Remove BENLYSTA IV from the refrigerator and allow to stand 10 to 15 minutes for the vial(s) to reach room temperature. Reconstitute BENLYSTA IV powder with Sterile Water for Injection, USP, as follows. The reconstituted solution will contain a concentration of 80 mg/mL belimumab. Use of a 21-to 25-gauge needle is recommended. Reconstitute the ... BENLYSTA diluted in normal saline, half-normal saline, or Lactated Ringer’s Injection may be stored at 36°F to 46°F (2°C to 8°C) or room temperature. The total time from reconstitution of BENLYSTA to completion of infusion should not exceed 8 hours. 9. No incompatibilities between BENLYSTA and polyvinylchloride or polyolefin bags have Benlysta é um medicamento usado no tratamento adicional de pacientes com lúpus eritematoso sistêmico (LES), uma doença em que o sistema imunológico ataca as células e tecidos normais, causando inflamação e dano aos órgãos. Esta ficha técnica contém informações essenciais sobre a composição, a indicação, a posologia, as reações adversas e as precauções de Benlysta, bem ... Benlysta binds to BLyS and prevents it from stimulating the growth of B cells, which may worsen your symptoms. Benlysta (pronounced ben-LIST-ah) is a prescription medicine used with other lupus treatments to treat active systemic lupus erythematosus (SLE) and active lupus nephritis (lupus-related kidney inflammation) in adults and children. Belimumab (Benlystasup®/sup) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE). Belimumab is approved in t …. Benlysta is administered intravenously by infusion, and must be reconstituted and diluted before administration. For instructions on reconstitution, dilution, and storage of the medicinal product before administration, see section 6.6. Benlysta should be infused over a 1-hour period. Benlysta must not be administered as an intravenous bolus.